Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Free Cash Flow (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Free Cash Flow for 6 consecutive years, with -$27.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 61.98% to -$27.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$82.2 million, a 86.17% decrease, with the full-year FY2025 number at -$82.2 million, down 86.17% from a year prior.
  • Free Cash Flow was -$27.6 million for Q4 2025 at Janux Therapeutics, down from -$13.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $5.4 million in Q1 2021 to a low of -$27.6 million in Q4 2025.
  • A 5-year average of -$12.3 million and a median of -$13.2 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 81.94% in 2024, then tumbled 504.75% in 2025.
  • Janux Therapeutics' Free Cash Flow stood at -$9.7 million in 2021, then plummeted by 44.52% to -$14.0 million in 2022, then increased by 25.43% to -$10.4 million in 2023, then crashed by 63.61% to -$17.0 million in 2024, then crashed by 61.98% to -$27.6 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Free Cash Flow are -$27.6 million (Q4 2025), -$13.7 million (Q3 2025), and -$23.5 million (Q2 2025).